POST-ACUTE COVID OUTCOMES: AMUBARVIMAB/ROMLUSEVIMAB VS PLACEBO IN THE ACTIV-2 TRIAL.
Autor: | Evering, Teresa H., Moser, Carlee, Jilg, Nikolaus, Ritz, Justin, Wohl, David A. |
---|---|
Zdroj: | Topics in Antiviral Medicine; Apr2023, Vol. 31 Issue 2, p286-286, 1/2p |
Databáze: | Complementary Index |
Externí odkaz: |